Researchers from the Massachusetts General Hospital have reported at the 2008, 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego, April 12-16.1 that Fareston® (toremifene citrate) decreases the risk of new vertebral fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). As we all know from our own [...]
Posted on the Prostate Problems Mailing list about two months ago was a notice from Dr. Richard Lam about a clinical trial in which his office, Prostate Oncology Specialists, will participate. What I found particularly interesting in this trial is that it was evaluating a potential new drug, abiraterone acetate, which could be used after [...]
The use of ADT is the treatment of choice for advanced, metastatic prostate cancer as long as the cancer is responsive to the blockade. The theory goes that the suppression of circulating testosterone, which fuels prostate-cancer growth, whether by surgical castration (orchiectomy) or castration with testosterone-blocking drugs slows down the progression of the prostate cancer. [...]
Are you taking Fosamax to help combat osteoporosis? Many of us take Fosamax as one of the most common side effects of a hormone blockade (ADT) is loss of bone density. ADT causes osteoporosis, or a decrease in bone density, which diminishes bone strength. A decrease in your bone density increases your chance to suffer [...]
April 14 in the Journal of Clinical Oncology reported that Eric M. Horwitz, M.D., from Fox Chase Cancer Center in Philadelphia, and colleagues treated 1,554 prostate cancer patients with goserelin and flutamide (ADT) before and during radiation therapy. The men were then randomly assigned to receive no further ADT or 24 additional months of ADT. [...]